Literature DB >> 666291

Cetocycline, tetracycline analog: in vitro studies of antimicrobial activity, serum binding, lipid solubility, and uptake by bacteria.

R Proctor, W Craig, C Kunin.   

Abstract

Cetocycline (formerly chelocardin or cetotetrine) is structurally related to the tetracyclines. It was found to be more active than tetracycline against many clinical isolates of aerobic gram-negative bacilli, but is less active against staphylococci, and has no activity against Pseudomonas. It is bactericidal against susceptible enteric gram-negative bacteria at concentrations two to four times higher than the minimal inhibiting concentrations. The drug is highly lipid soluble; more than 80% is bound to serum, and it is more avidly taken up by susceptible bacteria than tetracycline. A direct correlation between drug uptake and susceptibility of bacteria was not noted, except with a strain of Proteus vulgaris.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 666291      PMCID: PMC352294          DOI: 10.1128/AAC.13.4.598

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  INHIBITORS OF PENICILLIN BINDING TO SERUM PROTEINS.

Authors:  C M KUNIN
Journal:  J Lab Clin Med       Date:  1965-03

2.  Relation between lipophilicity and pharmacological behavior of minocycline, doxycycline, tetracycline, and oxytetracycline in dogs.

Authors:  M Barza; R B Brown; C Shanks; C Gamble; L Weinstein
Journal:  Antimicrob Agents Chemother       Date:  1975-12       Impact factor: 5.191

3.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

4.  Structure of chelocardin, a novel tetracycline antibiotic.

Authors:  L A Mitscher; J V Juvarkar; W Rosenbrook; W W Andres; J Schenk; R S Egan
Journal:  J Am Chem Soc       Date:  1970-10-07       Impact factor: 15.419

5.  Minocycline: Possible vestibular side-effects.

Authors:  D N Williams; L W Laughlin; Y H Lee
Journal:  Lancet       Date:  1974-09-28       Impact factor: 79.321

6.  pH-Partition behavior of tetracyclines.

Authors:  J L Colaizzi; P R Klink
Journal:  J Pharm Sci       Date:  1969-10       Impact factor: 3.534

7.  The disposition of doxycyline by man and dog.

Authors:  M Schach von Wittenau; T M Twomey
Journal:  Chemotherapy       Date:  1971       Impact factor: 2.544

8.  Cephalosporin and aminoglycoside concentrations in peritoneal capsular fluid in rabbits.

Authors:  D N Gerding; W H Hall; E A Schierl; R E Manion
Journal:  Antimicrob Agents Chemother       Date:  1976-12       Impact factor: 5.191

9.  Action of 12 tetracyclines on susceptible and resistant strains of Staphylococcus aureus.

Authors:  D Sompolinsky; J Krausz
Journal:  Antimicrob Agents Chemother       Date:  1973-09       Impact factor: 5.191

10.  Influence of magnesium and manganese on some biological and physical properties of tetracycline.

Authors:  D Sompolinsky; Z Samra
Journal:  J Bacteriol       Date:  1972-05       Impact factor: 3.490

View more
  4 in total

Review 1.  Tetracycline analogs whose primary target is not the bacterial ribosome.

Authors:  I Chopra
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

2.  Heterogeneity of tetracycline resistance determinants in Streptococcus.

Authors:  V Burdett; J Inamine; S Rajagopalan
Journal:  J Bacteriol       Date:  1982-03       Impact factor: 3.490

3.  Evidence that tetracycline analogs whose primary target is not the bacterial ribosome cause lysis of Escherichia coli.

Authors:  B Oliva; G Gordon; P McNicholas; G Ellestad; I Chopra
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

4.  Heterologous expression of the atypical tetracycline chelocardin reveals the full set of genes required for its biosynthesis.

Authors:  Tadeja Lukežič; Špela Pikl; Nestor Zaburannyi; Maja Remškar; Hrvoje Petković; Rolf Müller
Journal:  Microb Cell Fact       Date:  2020-12-19       Impact factor: 5.328

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.